Ken Griffin Dia Medica Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,300 shares of DMAC stock, worth $5,564. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,300
Previous 5,900
77.97%
Holding current value
$5,564
Previous $16,000
81.25%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DMAC
# of Institutions
34Shares Held
3.84MCall Options Held
1.3KPut Options Held
1K-
Vanguard Group Inc Valley Forge, PA1.02MShares$4.35 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$3.59 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX483KShares$2.07 Million3.48% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.64 Million0.41% of portfolio
-
Geode Capital Management, LLC Boston, MA237KShares$1.01 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $113M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...